524816 Stock Overview
A pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
NATCO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,426.90 |
| 52 Week High | ₹1,638.35 |
| 52 Week Low | ₹728.60 |
| Beta | 0.51 |
| 11 Month Change | 1.89% |
| 3 Month Change | 4.29% |
| 1 Year Change | 91.81% |
| 33 Year Change | 65.91% |
| 5 Year Change | 147.02% |
| Change since IPO | 50,860.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524816 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 10.4% | 1.5% | 0.004% |
| 1Y | 91.8% | 58.7% | 37.7% |
Return vs Industry: 524816 exceeded the Indian Pharmaceuticals industry which returned 58.7% over the past year.
Return vs Market: 524816 exceeded the Indian Market which returned 37.7% over the past year.
Price Volatility
| 524816 volatility | |
|---|---|
| 524816 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 524816 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524816's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,016 | Rajeev Nannapaneni | www.natcopharma.co.in |
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services.
NATCO Pharma Limited Fundamentals Summary
| 524816 fundamental statistics | |
|---|---|
| Market cap | ₹255.57b |
| Earnings (TTM) | ₹16.37b |
| Revenue (TTM) | ₹43.49b |
15.6x
P/E Ratio5.9x
P/S RatioIs 524816 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524816 income statement (TTM) | |
|---|---|
| Revenue | ₹43.49b |
| Cost of Revenue | ₹7.01b |
| Gross Profit | ₹36.48b |
| Other Expenses | ₹20.12b |
| Earnings | ₹16.37b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | 91.37 |
| Gross Margin | 83.89% |
| Net Profit Margin | 37.63% |
| Debt/Equity Ratio | 6.3% |
How did 524816 perform over the long term?
See historical performance and comparison